The Genzyme Corp. unit of Sanofi (Euronext:SAN; NYSE:SNY) will have access to at least eight of the nine RNAi therapeutics from the 5x15 rare disease pipeline of Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY), shown below. When the deal closes this quarter, Genzyme will receive selected rights to Alnylam's two most advanced candidates: patisiran and ALN-TTRsc.

For the two next most advanced assets, ALN-AT3 and ALN-AS1, Genzyme will have one of two options: either to co-develop and co-promote ALN-AT3 in North America and Western Europe and to take rights to